DOCSLIB.ORG

022345Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
022345Orig1s000 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022345Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) OFFICE OF CLINICAL PHARMACOLOGY REVIEW NDA: 22-345 Brand Name: Potiga™ Tablets Generic Name: Ezogabine Sponsor: Valeant Pharmaceuticals & GlaxoSmithKline Type of Dosage Form: Immediate release film-coated tablet Strengths: 50, 200, 300, and 400 mg Indication: Adjunctive treatment of partial onset seizures OCP Reviewers: Ta-Chen Wu, Ph.D. OCP Team Leader (Acting): Veneeta Tandon, Ph.D. OCP Division: DCP-1 HFD-860 OND Division: Division of Neurology Drug Products HFD-120 Submission Date: April 15, 2011 Type of Submission: Complete Response (Class 1) Resubmission BACKGROUND: The Sponsor submitted a complete response to the Agency’s Complete Response Letter, including labeling recommendation, dated November 30, 2010. The NDA 22-345 for POTIGA (ezogabine) tablets was originally submitted on October 30, 2009. The proposed indication is adjunctive treatment of partial onset seizures in patients 18 years of age and older. Noted in this complete response resubmission the Sponsor proposed to increase the maximum maintenance dose to 1200 mg/day (400 mg tid). To support the changes in labeling languages in Clinical Pharmacology sections, the Sponsor provided three supporting documents with respect to potential for digoxin interaction with ezogabine, hepatic impairment dosing guidance, and potential for antiepileptic drugs (AED) drug interaction with ezogabine. The main changes of the labeling recommendations are summarized below. 1. Potential for Digoxin Interaction with Ezogabine: Sections of digoxin interaction were added, as presented below. 7.2 Digoxin Data from an in vitro study showed that the N-acetyl metabolite of ezogabine (NAMR) inhibited P-glycoprotein–mediated transport of digoxin in a concentration- dependent manner, indicating that NAMR may inhibit renal clearance of digoxin. Administration of POTIGA at therapeutic doses may increase digoxin serum concentrations. Serum levels of digoxin should be monitored [see Clinical Pharmacology (12.3)]. 1 Reference ID: 2956199 (b) (4) Rationale: The N-acetyl metabolite of ezogabine (NAMR) inhibited digoxin transport in a concentration-dependent manner in an in-vitro study. Efflux inhibitions on P- glycoprotein (P-gp) transport activity for digoxin (a probe substrate) were 33%, 56%, and 70% with NAMR concentrations of 1μM (264ng/mL), 10μM (2643 ng/mL), and 100μM (26430 ng/mL), respectively. The I/IC50 ratios for NAMR were estimated to be >0.1, and thus the inhibitory potential on P-gp mediated digoxin elimination via kidney exists, especially when the maximum maintenance dose is increased to 1200 mg/day. The Table below details the mean steady-state NAMR concentrations observed in the pivotal clinical Study VRX-RET-E22-301 in epileptic patients and the correlation with the in vitro results. A formal IC50 for NAMR was not calculated however the value of 2643 ng/mL could be considered close to the IC50 value. OCP Recommendation: Based on an in vitro study, NAMR metabolite was found to be an inhibitor of the efflux transporter P-gp at concentrations of NAMR expected after administration of proposed doses therapeutic levels of ezogabine. Therefore, we request that the sponsor conduct a study in humans as a Post Marking Requirement (PMR) to investigate the impact of NAMR as an inhibitor for P-gp using digoxin as a probe substrate. 2. Hepatic Impairment Dosing Guidance: The Sponsor proposes to reduce the starting dose to half (i.e., 50 mg tid) and the maximum maintenance dose to 600 mg/day for patients with moderate hepatic impairment, as oppose to the 750 mg/day recommended by the Agency based on the approximate 50% increase in systemic exposure of ezogabine. Per the Sponsor, the proposed dosing regimens are based on the pharmacokinetic simulations for different starting doses. In addition, the starting dose of 100 mg tid would results in greater variability in this patient population. ”The predicted steady state ezogabine Cmax and AUC(0-24) values for the initial starting dose of 100 mg TID were generally similar to or 2 Reference ID: 2956199 higher than those predicted for healthy subjects, whereas, a reduction in the initial starting dose to 50 mg TID showed that the individual predicted steady state Cmax and AUC(0-24) values were completely contained within the range of the values predicted for healthy subjects.” With that, the sponsor proposed to reduce both starting and maintenance doses in patients with moderate hepatic impairment to ½. Reviewer’s comment: Based on results of the dedicated hepatic impairment study, the maintenance dose of 750 mg/day as recommended for patients with moderate impairment is expected to have similar AUC to that observed in healthy subjects; whereas the 600 mg/day would result in lower exposure. However, we do not consider the Sponsor’s arguments, including the in- house PK simulation, convincing against the maximum 750 mg/day in this patient population. In addition, details of the simulation to support the Sponsor’s claim were not available for the Agency’s review. Details of the dosing instruction are presented in “Section 4. Dosing Recommendations for Specific Populations”of this review. 3. Potential for AED Drug Interaction with Ezogabine: The Sponsor does not agree with FDA suggestion to include the information regarding phenytoin and carbamezepine from Study 3065A1-202 in the Drug Interaction Section (Section 7). Specifically, citing limited numbers of subjects in Study 3065A1-202, the Sponsor proposes to rely on results of population PK analysis of pooled data to show that concomitant AEDs had no significant impact on ezogabine. The Sponsor acknowledges the inducing effect of phenytoin and carbamezepine on ezogabine clearance but proposes no dose adjustment. Reviewer’s comment: The Agency believes that the numbers of the subjects, though relatively limited, who were on concomitant phenytoin and carbamezepine from this specific study were sufficient enough to warrant dosage adjustment based on the observed inducing effects. Therefore, the recommended labeling languages for the pertinent drug-interaction sections have been revised and presented in a tabular format, as shown below. 7. DRUG INTERACTIONS 7.1 Antiepileptic Drugs The potentially significant interactions between POTIGA™ and concomitant AEDs are summarized in the following Table: AED Dose of POTIGA™ Influence of Influence of AED Dosage AED Dose POTIGA™ on POTIGA™ Adjustment (mg/day) (mg/day) on AED Carbamazepine a * 600-2400 300-1200 None 31% decrease Consider an increase in in AUC; POTIGA™ dosage b 23% decrease in Cmax; Phenytoin a * 120-600 300-1200 None 34% decrease Consider an increase in in AUC; POTIGA™ dosage b 18% decrease in Cmax; a Based on trough concentrations in a Phase 2 study 3 Reference ID: 2956199 (b) (4) * Inducers for uridine 5'-diphosphate (UDP)-glucuronyltransferases (UGTs) [See Clinical Pharmacology (12.3)] 12.3 Pharmacolokinetcs Interactions with Antiepileptic Drugs: The interactions between POTIGA and concomitant AEDs are summarized in the following Table: AED a Dose of POTIGA Influence of Influence of AED Dosage AED Dose POTIGA on POTIGA Adjustment (mg/day) (mg/day) on AED Carbamazepine b * 600-2400 300-1200 None 31% decrease An increase in in AUC; POTIGA™ dosage 23% decrease in needs to be Cmax; considered c 28% increase in clearance; 5.3-hours shortening in half-life Phenytoin b * 120-600 300-1200 None 34% decrease An increase in in AUC; POTIGA™ dosage 18% decrease in needs to be Cmax; considered c 33% increase in clearance Topiramate b 250-1200 300-1200 None None None Valproate b 750-2250 300-1200 None None None Phenobarbital 90 600 None None None Lamotrigine 200 600 18% decrease in None None AUC; 22% increase in clearance; 5-hours shortening in half-life Others d None None None (b) (4) (b) (4) * Inducers for uridine 5'-diphosphate (UDP)-glucuronyltransferases (UGTs) 4. Dosing Recommendations for Specific Populations: Dosing Recommendations for Specific Populations in Section 2 of the label have been revised to a tabular format, as presented below. 2. DOSAGE AND ADMINISTRATION 2.1 Dosing Instructions 4 Reference ID: 2956199 Table 1. Dosing Recommendations Specific Population Initial Dose Titration Maximum Dose General Dosing General population 100 mg 3 times Increase by no more 400 mg 3 times (including patients daily than 50 mg 3 times daily with mild renal or (300 mg per day) daily, at weekly (1,200 mg per day) hepatic impairment) intervals Dosing in Specific Populations Geriatrics (patients >65 years) 50 mg 3 times daily 250 mg 3 times (150 mg per day) daily (750 mg per day) Renal impairment (patients with CrCL <50 mL per min or 50 mg 3 times daily 200 mg 3 times end-stage renal (150 mg per day) daily disease on dialysis) Increase by no more (600 mg per day) than 50 mg 3 times Hepatic impairment (patients with Child- 50 mg 3 times daily daily, at weekly 250 mg 3 times Pugh 7-9) per week intervals daily (150 mg per day) (750 mg per day) Hepatic impairment 200 mg 3 times (patients with Child- 50 mg 3 times daily daily Pugh >10) per week (600 mg per day) Deleted: / (150 mg per day) CONCLUSIONS AND RECOMMENDATIONS: The Office of Clinical Pharmacology/Division of Clinical Pharmacology 1 (OCP/DCP- 1) has reviewed the Sponsor’s complete response for the NDA 22-345, including the labeling, and finds it acceptable from an OCP perspective provided that the Sponsor agrees with the Phase IV commitment (PMR). In addition, agreement on the labeling language should be reached between the Sponsor and the Agency. PHASE IV RECOMMENDATIONS: The office of Clinical Pharmacology requests the following PMR: A study in humans for the evaluation of the acetyl metabolite of ezogabine (NAMR) as an inhibitor for P-glycoprotein (P-gp) using digoxin as a probe substrate 5 Reference ID: 2956199 Ta-Chen Wu, Ph.D.
Load more

Recommended publications
  • Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS
    Clinical, Forensic & Toxicology Article “The Big Pain”: Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS By Sharon Lupo As the use of prescription and nonprescription drugs grows, the need for fast, accurate, and comprehensive methods is also rapidly increasing. Historically, drug testing has focused on forensic applications such as cause of death determinations or the detection of drug use in specific populations (military, workplace, probation/parole, sports doping). However, modern drug testing has expanded well into the clinical arena with a growing list of target analytes and testing purposes. Clinicians often request the analysis of large panels of drugs and metabolites that can be used to ensure compliance with prescribed pain medication regimens and to detect abuse or diversion of medications. With prescription drug abuse reaching epidemic levels [1], demand is growing for analytical methods that can ensure accurate results for comprehensive drug lists with reasonable analysis times. LC-MS/MS is an excellent technique for this work because it offers greater sensitivity and specificity than immunoassay and—with a highly selective and retentive Raptor™ Biphenyl column—can provide definitive results for a wide range of compounds. Typically, forensic and pain management drug testing consists of an initial screening analysis, which is qualitative, quick, and requires only minimal sample preparation. Samples that test positive during screening are then subjected to a quantitative confirmatory analysis. Whereas screening assays may cover a broad list of compounds and are generally less sensitive and specific, confirmation testing provides fast, targeted analysis using chromatographic conditions that are optimized for specific panels.
    [Show full text]
  • Pharmacokinetic Drug–Drug Interactions Among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients
    International Journal of Molecular Sciences Review Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients Marta Kara´zniewicz-Łada 1 , Anna K. Główka 2 , Aniceta A. Mikulska 1 and Franciszek K. Główka 1,* 1 Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 60-781 Pozna´n,Poland; [email protected] (M.K.-Ł.); [email protected] (A.A.M.) 2 Department of Bromatology, Poznan University of Medical Sciences, 60-354 Pozna´n,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-(0)61-854-64-37 Abstract: Anti-epileptic drugs (AEDs) are an important group of drugs of several generations, rang- ing from the oldest phenobarbital (1912) to the most recent cenobamate (2019). Cannabidiol (CBD) is increasingly used to treat epilepsy. The outbreak of the SARS-CoV-2 pandemic in 2019 created new challenges in the effective treatment of epilepsy in COVID-19 patients. The purpose of this review is to present data from the last few years on drug–drug interactions among of AEDs, as well as AEDs with other drugs, nutrients and food. Literature data was collected mainly in PubMed, as well as google base. The most important pharmacokinetic parameters of the chosen 29 AEDs, mechanism of action and clinical application, as well as their biotransformation, are presented. We pay a special attention to the new potential interactions of the applied first-generation AEDs (carba- Citation: Kara´zniewicz-Łada,M.; mazepine, oxcarbazepine, phenytoin, phenobarbital and primidone), on decreased concentration Główka, A.K.; Mikulska, A.A.; of some medications (atazanavir and remdesivir), or their compositions (darunavir/cobicistat and Główka, F.K.
    [Show full text]
  • Preventive Report Appendix
    Title Authors Published Journal Volume Issue Pages DOI Final Status Exclusion Reason Nasal sumatriptan is effective in treatment of migraine attacks in children: A Ahonen K.; Hamalainen ML.; Rantala H.; 2004 Neurology 62 6 883-7 10.1212/01.wnl.0000115105.05966.a7 Deemed irrelevant in initial screening Seasonal variation in migraine. Alstadhaug KB.; Salvesen R.; Bekkelund SI. Cephalalgia : an 2005 international journal 25 10 811-6 10.1111/j.1468-2982.2005.01018.x Deemed irrelevant in initial screening Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Amery WK. 1983 Headache 23 2 70-4 10.1111/j.1526-4610.1983.hed2302070 Deemed irrelevant in initial screening Monoamine oxidase inhibitors in the control of migraine. Anthony M.; Lance JW. Proceedings of the 1970 Australian 7 45-7 Deemed irrelevant in initial screening Prostaglandins and prostaglandin receptor antagonism in migraine. Antonova M. 2013 Danish medical 60 5 B4635 Deemed irrelevant in initial screening Divalproex extended-release in adolescent migraine prophylaxis: results of a Apostol G.; Cady RK.; Laforet GA.; Robieson randomized, double-blind, placebo-controlled study. WZ.; Olson E.; Abi-Saab WM.; Saltarelli M. 2008 Headache 48 7 1012-25 10.1111/j.1526-4610.2008.01081.x Deemed irrelevant in initial screening Divalproex sodium extended-release for the prophylaxis of migraine headache in Apostol G.; Lewis DW.; Laforet GA.; adolescents: results of a stand-alone, long-term open-label safety study. Robieson WZ.; Fugate JM.; Abi-Saab WM.; 2009 Headache 49 1 45-53 10.1111/j.1526-4610.2008.01279.x Deemed irrelevant in initial screening Safety and tolerability of divalproex sodium extended-release in the prophylaxis of Apostol G.; Pakalnis A.; Laforet GA.; migraine headaches: results of an open-label extension trial in adolescents.
    [Show full text]
  • Chapter 25 Mechanisms of Action of Antiepileptic Drugs
    Chapter 25 Mechanisms of action of antiepileptic drugs GRAEME J. SILLS Department of Molecular and Clinical Pharmacology, University of Liverpool _________________________________________________________________________ Introduction The serendipitous discovery of the anticonvulsant properties of phenobarbital in 1912 marked the foundation of the modern pharmacotherapy of epilepsy. The subsequent 70 years saw the introduction of phenytoin, ethosuximide, carbamazepine, sodium valproate and a range of benzodiazepines. Collectively, these compounds have come to be regarded as the ‘established’ antiepileptic drugs (AEDs). A concerted period of development of drugs for epilepsy throughout the 1980s and 1990s has resulted (to date) in 16 new agents being licensed as add-on treatment for difficult-to-control adult and/or paediatric epilepsy, with some becoming available as monotherapy for newly diagnosed patients. Together, these have become known as the ‘modern’ AEDs. Throughout this period of unprecedented drug development, there have also been considerable advances in our understanding of how antiepileptic agents exert their effects at the cellular level. AEDs are neither preventive nor curative and are employed solely as a means of controlling symptoms (i.e. suppression of seizures). Recurrent seizure activity is the manifestation of an intermittent and excessive hyperexcitability of the nervous system and, while the pharmacological minutiae of currently marketed AEDs remain to be completely unravelled, these agents essentially redress the balance between neuronal excitation and inhibition. Three major classes of mechanism are recognised: modulation of voltage-gated ion channels; enhancement of gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission; and attenuation of glutamate-mediated excitatory neurotransmission. The principal pharmacological targets of currently available AEDs are highlighted in Table 1 and discussed further below.
    [Show full text]
  • 8Th European Congress on Epileptology, Berlin, Germany, 21 – 25 September 2008
    Epilepsia, 50(Suppl. 4): 2–262, 2009 doi: 10.1111/j.1528-1167.2009.02063.x 8th ECE PROCEEDINGS 8th European Congress on Epileptology, Berlin, Germany, 21 – 25 September 2008 Sunday 21 September 2008 KV7 channels (KV7.1-5) are encoded by five genes (KCNQ1-5). They have been identified in the last 10–15 years by discovering the caus- 14:30 – 16:00 ative genes for three autosomal dominant diseases: cardiac arrhythmia Hall 1 (long QT syndrome, KCNQ1), congenital deafness (KCNQ1 and KCNQ4), benign familial neonatal seizures (BFNS, KCNQ2 and VALEANT PHARMACEUTICALS SATELLITE SYM- KCNQ3), and peripheral nerve hyperexcitability (PNH, KCNQ2). The fifth member of this gene family (KCNQ5) is not affected in a disease so POSIUM – NEURON-SPECIFIC M-CURRENT K+ CHAN- far. The phenotypic spectrum associated with KCNQ2 mutations is prob- NELS: A NEW TARGET IN MANAGING EPILEPSY ably broader than initially thought (i.e. not only BFNS), as patients with E. Perucca severe epilepsies and developmental delay, or with Rolando epilepsy University of Pavia, Italy have been described. With regard to the underlying molecular pathophys- iology, it has been shown that mutations in KCNQ2 and KCNQ3 Innovations in protein biology, coupled with genetic manipulations, have decrease the resulting K+ current thereby explaining the occurrence of defined the structure and function of many of the voltage- and ligand- epileptic seizures by membrane depolarization and increased neuronal gated ion channels, channel subunits, and receptors that are the underpin- firing. Very subtle changes restricted to subthreshold voltages are suffi- nings of neuronal hyperexcitability and epilepsy. Of the currently cient to cause BFNS which proves in a human disease model that this is available antiepileptic drugs (AEDs), no two act in the same way, but all the relevant voltage range for these channels to modulate the firing rate.
    [Show full text]
  • Diazepam and Kava Combination Article
    Journal of Advanced Research (2014) 5, 587–594 Cairo University Journal of Advanced Research ORIGINAL ARTICLE Enhanced efficacy and reduced side effects of diazepam by kava combination Rasha A. Tawfiq a, Noha N. Nassar b,*, Wafaa I. El-Eraky c, Ezzeldein S. El-Denshary b a Egyptian Patent Office, Academy of Scientific Research and Technology, 101 Kasr El-Eini St., Cairo, Egypt b Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Eini St., Cairo, Egypt c Department of Pharmacology, National Research Center, El-Tahrir St., Giza, Egypt ARTICLE INFO ABSTRACT Article history: The long term use of antiepileptic drugs possesses many unwanted effects; thus, new safe com- Received 2 April 2013 binations are urgently mandated. Hence, the present study aimed to investigate the anticonvul- Received in revised form 18 July 2013 sant effect of kava alone or in combination with a synthetic anticonvulsant drug, diazepam Accepted 15 August 2013 (DZ). To this end, female Wistar rats were divided into two subsets, each comprising 6 groups Available online 22 August 2013 as follows: group (i) received 1% Tween 80 p.o. and served as control, while groups (ii) and (iii) received kava at two dose levels (100 and 200 mg/kg, p.o.). The remaining three groups received Keywords: (iv) DZ alone (10 mg/kg p.o.) or kava in combination with DZ (v) (5 mg/kg, p.o.) or (vi) (10 mg/ Kava kg, p.o.). Results of the present study revealed that kava increased the maximal electroshock Diazepam seizure threshold (MEST) and enhanced the anticonvulsant effect of diazepam following both Anticonvulsant acute and chronic treatment.
    [Show full text]
  • Therapeutic Drug Monitoring of Antiepileptic Drugs by Use of Saliva
    REVIEW ARTICLE Therapeutic Drug Monitoring of Antiepileptic Drugs by Use of Saliva Philip N. Patsalos, FRCPath, PhD*† and Dave J. Berry, FRCPath, PhD† INTRODUCTION Abstract: Blood (serum/plasma) antiepileptic drug (AED) therapeu- Measuring antiepileptic drugs (AEDs) in serum or tic drug monitoring (TDM) has proven to be an invaluable surrogate plasma as an aid to personalizing drug therapy is now a well- marker for individualizing and optimizing the drug management of established practice in the treatment of epilepsy, and guidelines patients with epilepsy. Since 1989, there has been an exponential are published that indicate the particular features of epilepsy and increase in AEDs with 23 currently licensed for clinical use, and the properties of AEDs that make the practice so beneficial.1 recently, there has been renewed and extensive interest in the use of The goal of AED therapeutic drug monitoring (TDM) is to saliva as an alternative matrix for AED TDM. The advantages of saliva ’ fl optimize a patient s clinical outcome by supporting the man- include the fact that for many AEDs it re ects the free (pharmacolog- agement of their medication regimen with the assistance of ically active) concentration in serum; it is readily sampled, can be measured drug concentrations/levels. The reason why TDM sampled repetitively, and sampling is noninvasive; does not require the has emerged as an important adjunct to treatment with the expertise of a phlebotomist; and is preferred by many patients, AEDs arises from the fact that for an individual patient
    [Show full text]
  • PR2 2009.Vp:Corelventura
    Pharmacological Reports Copyright © 2009 2009, 61, 197216 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Review Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions Jarogniew J. £uszczki1,2 Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, PL 20-090 Lublin, Poland Department of Physiopathology, Institute of Agricultural Medicine, Jaczewskiego 2, PL 20-950 Lublin, Poland Correspondence: Jarogniew J. £uszczki, e-mail: [email protected]; [email protected] Abstract: This review briefly summarizes the information on the molecular mechanisms of action, pharmacokinetic profiles and drug interac- tions of novel (third-generation) antiepileptic drugs, including brivaracetam, carabersat, carisbamate, DP-valproic acid, eslicar- bazepine, fluorofelbamate, fosphenytoin, ganaxolone, lacosamide, losigamone, pregabalin, remacemide, retigabine, rufinamide, safinamide, seletracetam, soretolide, stiripentol, talampanel, and valrocemide. These novel antiepileptic drugs undergo intensive clinical investigations to assess their efficacy and usefulness in the treatment of patients with refractory epilepsy. Key words: antiepileptic drugs, brivaracetam, carabersat, carisbamate, DP-valproic acid, drug interactions, eslicarbazepine, fluorofelbamate, fosphenytoin, ganaxolone, lacosamide, losigamone, pharmacokinetics, pregabalin, remacemide, retigabine, rufinamide, safinamide, seletracetam, soretolide, stiripentol, talampanel, valrocemide Abbreviations: 4-AP
    [Show full text]
  • A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache
    University of South Florida Masthead Logo Scholar Commons School of Information Faculty Publications School of Information 7-2015 A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache Authors: Jeffrey L. Jackson, Elizabeth Cogbill, Rafael Santana-Davila, Christina Eldredge, William Collier, Andrew Gradall, Neha Sehgal, and Jessica Kuester OBJECTIVE: To compare the effectiveness and side effects of migraine prophylactic medications. DESIGN: We performed a network meta-analysis. Data were extracted independently in duplicate and quality was assessed using both the JADAD and Cochrane Risk of Bias instruments. Data were pooled and network meta-analysis performed using random effects models. DATA SOURCES: PUBMED, EMBASE, Cochrane Trial Registry, bibliography of retrieved articles through 18 May 2014. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We included randomized controlled trials of adults with migraine headaches of at least 4 weeks in duration. RESULTS: Placebo controlled trials included alpha blockers (n = 9), angiotensin converting enzyme inhibitors (n = 3), angiotensin receptor blockers (n = 3), anticonvulsants (n = 32), beta-blockers (n = 39), calcium channel blockers (n = 12), flunarizine (n = 7), serotonin reuptake inhibitors (n = 6), serotonin norepinephrine reuptake inhibitors (n = 1) serotonin agonists (n = 9) and tricyclic antidepressants (n = 11). In addition there were 53 trials comparing different drugs. Drugs with at least 3 trials that were more effective than placebo for episodic migraines
    [Show full text]
  • Identification of Channels Underlying the M-Like Potassium Current In
    Identification of channeis underiying the M-like potassium current in NG108-15 neurobiastoma-giioma ceiis A thesis submitted for the degree of Doctor of Philosophy University of London by Jennifer Kathleen Hadley Department of Pharmacology University College London Gower Street London WC1E 6BT ProQuest Number: U644085 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U644085 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract NG108-15 cells express a potassium current resembling the IVI-current found in sympathetic ganglia. I contributed to the identification of the channels underlying this NG108-15 current. I used patch-clamp methodology to characterise the kinetics and pharmacology of the M-like current and of three candidate channel genes, all capable of producing “delayed rectifier” currents, expressed in mammalian cells. I studied two Kvi .2 clones: NGK1 (rat Kvi .2) expressed in mouse fibroblasts, and MK2 (mouse brain Kvi .2) expressed in Chinese hamster ovary (OHO) cells. Kvi.2 showed relatively positive activation that shifted negatively on repeated activation, some inactivation, block by dendrotoxin and various cations, and activation by niflumic acid.
    [Show full text]
  • Tegretol (Carbamazepine)
    Page 3 Tegretol® carbamazepine USP Chewable Tablets of 100 mg - red-speckled, pink Tablets of 200 mg – pink Suspension of 100 mg/5 mL Tegretol®-XR (carbamazepine extended-release tablets) 100 mg, 200 mg, 400 mg Rx only Prescribing Information WARNING SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH TEGRETOL. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT- RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH TEGRETOL. PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH TEGRETOL UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK (SEE WARNINGS AND PRECAUTIONS/LABORATORY TESTS). APLASTIC ANEMIA AND AGRANULOCYTOSIS APLASTIC ANEMIA AND AGRANULOCYTOSIS HAVE BEEN REPORTED IN ASSOCIATION WITH THE USE OF TEGRETOL. DATA FROM A POPULATION-BASED CASE CONTROL STUDY DEMONSTRATE THAT THE RISK OF DEVELOPING THESE REACTIONS IS 5-8 TIMES GREATER THAN IN THE GENERAL POPULATION. HOWEVER, THE OVERALL RISK OF THESE REACTIONS IN THE UNTREATED GENERAL POPULATION IS LOW, APPROXIMATELY SIX PATIENTS PER ONE MILLION POPULATION PER YEAR FOR AGRANULOCYTOSIS AND TWO PATIENTS PER ONE MILLION POPULATION PER YEAR FOR APLASTIC ANEMIA.
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]